RE:RE:What happened with the scleroderma indication?On friday I followed up with Fred on Scleroderma, AAT and C1 INH, all of which had little to no mention in the CC. I am told timelines are still as presented at the AGM.
On IPF, it certainly sounds like they have decided not to do the add-on trail in the US. But PL still spoke positively of results in lungs. Almost sounds like the don't care to be an add-on, but have a different strategy as to how they will approach it. I guess we will see in the fall.
IMHO